exhibit 10. 1 fourth addendum to asset purchase agreement this fourth addendum to asset purchase agreement ( “ fourth addendum ” ) is effective as on the date the parties have fully signed the fourth addendum ( “ effective date of the fourth addendum ” ) and memorializes an agreement reached between pharmacyte biotech, inc., formerly nuvilex, inc. ( “ licensee ” ), and sg austria pte. ltd. ( “ licensor ” ) on 30 august 2017, as amended, relating to the asset purchase agreement between the parties dated as of the 26th day of may 2011 ( “ asset purchase agreement ” ), as amended by the asset purchase agreement addendum dated as of june 11, 2011, the asset purchase agreement addendum number 2 dated as of june 14, 2012, the december 3, 2012 extension letter from sg austria, the third addendum to asset purchase agreement dated as of june 25, 2013 ( “ third addendum ” ) and the clarification agreement to third addendum to asset purchase agreement dated as of june 25, 2013 ( “ clarification agreement ” ). licensee and licensor are referred to in this fourth addendum individually as a “ party ” and collectively as the “ parties. ” defined terms in the asset purchase agreement, third addendum and clarification agreement ( collectively, “ agreements ” ) have the same meaning in this fourth addendum as they do in the agreements. recitals a. the parties entered into the licensing agreement to, among other things, provide licensee with an exclusive worldwide license to use the cell - in - a - box® trademark and its associated technology with genetically modified hek293 cells overexpressing the cytochrome p450 2b1 gene specifically designed for the treatment of cancer to conduct research, to use in preclinical studies and clinical trials, to obtain marketing approval and to market and sell products and treatments utilizing the cell - in - a - box® trademark and its associated technology world - wide ; a. the parties entered into the licensing agreement to, among other things, provide licensee with an exclusive worldwide license to use the cell - in - a - box® trademark and its associated technology with genetically modified hek293 cells overexpressing the cytochrome p450 2b1 gene specifically designed for the treatment of cancer to conduct research, to use in